Merck & Company (MRK) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Merck & Company (MRK)

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

119.60

+0.08 (0.07%)

as of Jun 9, 2026, 8:00:00 pm Market Open.

310 watching

Investor Insights

Jun 9, 2026, 12:00 am

This summary was created by AI, based on 21 opinions in the last 12 months.

Merck & Company (MRK) is widely recognized for its robust drug pipeline, particularly in the oncology space, despite concerns surrounding the impending patent expiration of its blockbuster drug Keytruda in 2028, which currently accounts for a significant portion of its revenue. Experts express mixed sentiments on its future performance; while some highlight the strong growth prospects from various drugs in the pipeline and strategic acquisitions, others point to risks and valuation concerns in light of the upcoming patent cliff. Analysts have shown optimism regarding MRK's capacity to sustain revenue growth post-Keytruda, often citing its decent dividend yield and potential for substantial upside. Overall, the company has been recommended as a solid investment, with a call for cautious management of positions amid broader market uncertainty and clarity on US drug pricing affecting the pharmaceutical sector.

Consensus

Bullish

Valuation

Undervalued

Similar

Pfizer, PFE

HOLD

Sell PFE to buy MRK? Likes and owns them both. MRK is more in the immuno oncology and cancer space, whereas PFE is more diversified. Defensive and growth characteristics. MRK hit a new high today. PFE hasn't done as well, but has performed over the last 2 years. Own both for different reasons. May want to trim in early part of next cycle. Yield is 2.6%.

BUY

Allan Tong’s Discover Picks Merck is definitely on an uptrend, breaking past $100 as October ends to establish new 52-week highs. The stock’s catalyst was its sterling Q3 report last week where it beat earnings and revenues and upgraded its forecast. Year-over-year, earnings were up 4% (7% if you exclude the impact of the strong USD) and revenues rose 14% (18% considering currency). Drivers were strong sales of Merck’s cancer drugs and many vaccines. The pharmaceutical side boasted a 13% hike in sales YOY. Merck’s key drug, Keytruda, saw sales jump 20%. One of the new weaknesses in Merck was its animal health business where the strong greenback depressed sales by 3%. Read 3 Must Have Safe Stocks to Play Defensive for our full analysis.

PAST TOP PICK

(A Top Pick Oct 21/21, Up 25%) Broken out to new highs. Yield is 2.8%, which should grow 8-9% over next few years. Well-positioned in immune oncology. Strong drug pipeline.

BUY

Their report won't disrupt their momentum. The stock is breaking out now to $100. He's maintaining his position. One of his favourite names.

Premium content

It's a Monthly Gems opinion which is available only for Stockchase Premium

Curated by Allan Tong since 2019.
99+ opinions with 4.15 rating.

TOP PICK

Some concrete good news: Recently, Merck won a patent infringement suit against Viatris that will prevent the drugs Januvia and Janumet from seeing generic versions until May 2026.
As you watch the trial results of these various drugs, you will collect a 3.18% dividend yield and sleep well at a 0.34 beta. The street has 10 buys, two holds and a $100.64 price target.

BUY

Has owned this since the mid-$80s. It offers the perfect blend of offence and defence perfectly. Investors have ignored this, but boasts a 20% a valuation discount to the S&P. You must be defensive, and Merck is a leader in healthcare.

HOLD

When you're looking at pharma companies, you want to see the breadth of drugs that are in the pipeline, and any blockbuster drugs in there. You're also looking for dividends. Yield is 3.17%.

HOLD

Company is on watch list. Does not own shares. Current share price target on the street is ~$100. Is cheaper valued than rest of the market (12x earnings). Has lower patent rate than competitors.

TOP PICK

Acquisition from last year has expanded product offering. Covid-19 pandemic was hard on company, but is recovering now. Company is a defensive name as drug prices are inelastic (medications are hard to give up). Strong cash flow and dividend.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Mar 24/22, Up 5.7%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with MRK has triggered its stop at $855. To remain disciplined we recommend covering the position at this time. This will result in a net investment gain of 8%, when combined with previous buy recommendations.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Mar 24/22, Up 13.7%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with MRK is progressing well. To remain disciplined, we recommend trailing up the stop (from $80) to $85.

BUY

Reasonable and sustainable multiple of 12x and very good dividend. Major drug is patent-protected until at least 2026, plus great drugs in pipeline.

PAST TOP PICK

(A Top Pick May 08/20, Up 36%) Loves it. A bit pricey here. Model price of $122.65, a 31% upside. In bear markets, people go for predictable earnings. Good bear market stock. Wait for a pullback to buy, under $70. Over 3% yield.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Mar 24/22, Up 15%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with MRK has achieved its $92.50 target. To remain disciplined, we recommend covering half the position at this time and trailing up the stop (from $74) to $80.

TOP PICK

Growth focused, but a real business. Safety. Second-largest in animal health, diversified oncology. Visibility and pricing power. Roche's miss in immunotherapy reinforces MRK's leadership position in that area. Not expensive. 13x earnings for near double-digit EPS growth. Yield is 3.09%. (Analysts’ price target is $96.34)

Showing 76 to 90 of 304 entries

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Barry Schwartz

Baskin Wealth Management

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Mike Vinokur, CFA, CMT, and CFP

Propellus Wealth Partners/iA Private Wealth

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Merck & Company (MRK)